Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Nivolumab in MMR Proficient Advanced Refractory Colorectal Cancer
NCT03712943Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of regorafenib and nivolumab in colorectal cancer (CRC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Oct 2018; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03712943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712943.